Last reviewed · How we verify

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge

University of Wisconsin, Madison · FDA-approved active Small molecule Quality 17/100

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge is a Nicotine replacement therapy (NRT) Small molecule drug developed by University of Wisconsin, Madison. It is currently FDA-approved. Also known as: Cessation Phase Combination NRT.

The combination of Cessation Phase Nicotine Patch and Nicotine Mini-Lozenge is a smoking cessation therapy developed by the University of Wisconsin, Madison. This dual-therapy approach aims to reduce nicotine withdrawal symptoms and cravings by providing a steady dose of nicotine through the patch and additional doses via lozenges as needed. The treatment is designed to help smokers gradually reduce their dependence on cigarettes. While there is no FDA label, the therapy has shown promise in clinical trials and is being evaluated for broader use. Common side effects include nausea, headache, and dizziness, which are generally mild to moderate in severity.

At a glance

Generic nameCessation Phase Nicotine Patch + Nicotine Mini-Lozenge
Also known asCessation Phase Combination NRT
SponsorUniversity of Wisconsin, Madison
Drug classNicotine replacement therapy (NRT)
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge

What is Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge is a Nicotine replacement therapy (NRT) drug developed by University of Wisconsin, Madison.

Who makes Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge is developed and marketed by University of Wisconsin, Madison (see full University of Wisconsin, Madison pipeline at /company/university-of-wisconsin-madison).

Is Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge also known as anything else?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge is also known as Cessation Phase Combination NRT.

What drug class is Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge in?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge belongs to the Nicotine replacement therapy (NRT) class. See all Nicotine replacement therapy (NRT) drugs at /class/nicotine-replacement-therapy-nrt.

What development phase is Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge in?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge is FDA-approved (marketed).

What does Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge target?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge targets Nicotinic acetylcholine receptors and is a Nicotine replacement therapy (NRT).

Related